GATA binding protein 6 ( GATA6 ) is co-amplified with PIK3CA in patients with esophageal adenocarcinoma and is linked to neoadjuvant therapy
ConclusionsOur study investigates the relevance ofGATA6 amplification on a large tumor collective, which includes primary resected tumors and the clinically relevant group of neoadjuvant treated EACs. Especially in the pretreated group, we found an accumulation ofGATA6-amplified tumors (12.3%) and a frequent co-amplification ofPIK3CA. Our data suggest an increased resistance to radio-chemotherapy inGATA6-amplified tumors.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | Esophagus Cancer | Fish | Genetics | Molecular Biology | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Study